Cross-institution positioning
Aug 6, 2026Reduction leaning. 1 reducing across 1 comparable institution.
Source: Schedule 13 researchMineralys Therapeutics, Inc.
Latest stored close $23.37 as of Oct 9, 2026 View live quote ↗
See how each tracked institution's reported ownership changed across SEC position dates. Full history is available with Investor or Pro access.
What the evidence shows across the newest institutional, insider, company-event, 13F, fundamental, and price data; STOCKNODE combines these layers into a quantitative research signal while preserving each source and reporting window.
Reduction leaning. 1 reducing across 1 comparable institution.
Source: Schedule 13 research2 increased/new, 0 reduced/exited across 2 managers in the latest comparable Form 13F quarter.
Source: Form 13F quarter-end holdingsOver the last 90 days, SEC-coded non-derivative P/S activity includes 0 purchases by 0 reporting owners and 12 sales by 5 reporting owners. Amendments are shown in the filing evidence but excluded from rolling activity totals.
Source: SEC Forms 3/4/51 non-amendment material event in the last 90 days; Latest classified evidence: Results of operations / financial condition. Registration and prospectus filings are treated as financing capacity/disclosure evidence, not proof that securities were sold.
Source: SEC 8-K / securities filing metadataNet income -457.1% YoY. Periods are compared only when the SEC facts are aligned and comparable.
Source: SEC Company FactsRecent close is 26% through its reported 52-week range; -20.2% over one year.
Source: Stored historical price seriesFiled Aug 6, 2026. Unlock the dated position comparison, disclosure classification, confidence, price context, and filing-specific significance analysis.
Premium research values are withheld until unlocked.
The research summary above gives the current read. This section shows the dated holder-level evidence behind it.
See each institution's newest reported position against its own prior report, with position as-of date separated from SEC filed date. Institution names and filing freshness remain public below.
Comparable holder direction grouped by SEC position as-of date — never presented as trade dates.
Compare each institution only with its own prior reported position. Public visitors can see who is tracked and how fresh the filing is; paid research reveals the actual comparison.
Investor and Pro reveal holder-by-holder changes, reported ownership history, dated breadth, disclosure timing, institution comparison, and filing-specific analysis without treating Schedule 13 reports as trade dates.
Reported Section 16 ownership activity. Rolling purchase/sale totals use non-derivative SEC transaction codes P and S only; amendments remain visible but are excluded from those totals.
| Date | Reporting owner | Code | Security | Shares | Price | Ownership | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Congleton Jon | SOpen-market or private sale | Common Stock | 75.0K | $25.46 | Direct | Oct 2, 2026 |
| Sep 22, 2026 | Slingsby Brian Taylor | SOpen-market or private sale | Common Stock | 104.3K | $28.81 | Indirect | Sep 24, 2026 |
| Sep 21, 2026 | Warren Eric | MExercise or conversion of derivative · derivative | Stock Option | 7.4K | $0.00 | Direct | Sep 22, 2026 |
| Sep 21, 2026 | Warren Eric | SOpen-market or private sale | Common Stock | 7.4K | $28.12 | Direct | Sep 22, 2026 |
| Sep 21, 2026 | Warren Eric | MExercise or conversion of derivative | Common Stock | 7.4K | $13.24 | Direct | Sep 22, 2026 |
| Sep 15, 2026 | Karydas Daphne | MExercise or conversion of derivative · derivative | Stock Option | 3.0K | $0.00 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Karydas Daphne | SOpen-market or private sale | Common Stock | 3.0K | $28.58 | Direct | Sep 17, 2026 |
| Sep 15, 2026 | Karydas Daphne | MExercise or conversion of derivative | Common Stock | 3.0K | $12.02 | Direct | Sep 17, 2026 |
| Aug 21, 2026 | Warren Eric | MExercise or conversion of derivative · derivative | Stock Option | 7.4K | $0.00 | Direct | Aug 25, 2026 |
| Aug 21, 2026 | Warren Eric | SOpen-market or private sale | Common Stock | 7.4K | $25.98 | Direct | Aug 25, 2026 |
| Aug 21, 2026 | Warren Eric | MExercise or conversion of derivative | Common Stock | 7.4K | $13.24 | Direct | Aug 25, 2026 |
| Aug 10, 2026 | Ferguson James J. III | AGrant, award, or other acquisition · derivative | Stock Option | 135.0K | $0.00 | Direct | Aug 12, 2026 |
| Aug 10, 2026 | Ferguson James J. III | AGrant, award, or other acquisition | Common Stock | 102.4K | $0.00 | Direct | Aug 12, 2026 |
| Aug 10, 2026 | Rodman David Malcom | MExercise or conversion of derivative · derivative | Stock Option | 2.2K | $0.00 | Direct | Aug 12, 2026 |
| Aug 10, 2026 | Rodman David Malcom | SOpen-market or private sale | Common Stock | 2.2K | $27.09 | Direct | Aug 12, 2026 |
| Aug 10, 2026 | Rodman David Malcom | MExercise or conversion of derivative | Common Stock | 2.2K | $16.00 | Direct | Aug 12, 2026 |
| Jul 21, 2026 | Warren Eric | MExercise or conversion of derivative · derivative | Stock Option | 7.4K | $0.00 | Direct | Jul 23, 2026 |
| Jul 21, 2026 | Warren Eric | SOpen-market or private sale | Common Stock | 7.4K | $26.87 | Direct | Jul 23, 2026 |
| Jul 21, 2026 | Warren Eric | MExercise or conversion of derivative | Common Stock | 7.4K | $13.24 | Direct | Jul 23, 2026 |
| Jul 17, 2026 | Rodman David Malcom | MExercise or conversion of derivative · derivative | Stock Option | 416 | $0.00 | Direct | Jul 20, 2026 |
Recent 8-K item classifications plus securities registration and prospectus filings. Registration or prospectus filings show financing capacity/disclosure activity; they do not by themselves prove that securities were sold.
| Filed | Form | 8-K item(s) | Classification | Capital context | SEC |
|---|---|---|---|---|---|
| Aug 11, 2026 | 8-K | 2.02, 5.02, 9.01 | Results of operations / financial condition; Director or executive change; Financial statements / exhibits | — | Filing |
| Jun 3, 2026 | 8-K | 8.01, 9.01 | Other event; Financial statements / exhibits | — | Filing |
| Jun 3, 2026 | 424B5 | — | Prospectus filing | Capital-related | Filing |
| Jun 3, 2026 | 8-K | 1.01, 2.03 | Material definitive agreement; New direct financial obligation | Debt | Filing |
| May 22, 2026 | 8-K | 5.07, 9.01 | Shareholder vote results; Financial statements / exhibits | — | Filing |
| May 6, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Mar 12, 2026 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
| Mar 9, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Feb 13, 2026 | S-8 | — | Employee-plan securities registration | Equity | Filing |
| Jan 6, 2026 | 8-K | 7.01, 8.01, 9.01 | Regulation FD disclosure; Other event; Financial statements / exhibits | — | Filing |
| Nov 10, 2025 | S-3ASR | — | Shelf securities registration | Capital-related | Filing |
| Nov 10, 2025 | 8-K | 2.02, 9.01 | Results of operations / financial condition; Financial statements / exhibits | — | Filing |
Period-aligned SEC facts. Comparisons appear only when periods and units are comparable.
Dated price context from the historical market series already collected for this security.
Returns are close-to-close price changes. Volatility and drawdown are factual historical context, not recommendations.
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
For more context, see how to read a Schedule 13G, filing date vs event date, or Schedule 13G vs Schedule 13D.
| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| Fidelity / FMR CIK0000315066 | Jun 30, 2026 observed Aug 6, 2026 filed · 37d Schedule 13G amendment | Reported reduction | 4.5K -5.0M | 5.10% -6.90 pts | $26.98 | $26.99 | $23.37 |
| Fidelity / FMR CIK0000315066 | Dec 31, 2025 observed Feb 5, 2026 filed · 36d Initial Schedule 13G | Initial Schedule 13G | 5.0M | 12.00% | $36.29 | $28.21 | $23.37 |
| BlackRock CIK0002012383 | Dec 31, 2025 observed Jan 21, 2026 filed · 21d Initial Schedule 13G | Initial Schedule 13G | 4.1M | 12.00% | $36.29 | $31.31 | $23.37 |
Compare MLYS with other securities showing similar institutional activity or recent accumulation across several tracked institutions.